Temasek-backed Chinese biotech firm D3 Bio raises $62m in Series A+ round
European life sciences investment firm Medicxi led the round with a $40 million investment.
Source: dealstreetasia.com
Stay updated with breaking news from Boyu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
European life sciences investment firm Medicxi led the round with a $40 million investment.
Life sciences investment firm Medicxi has injected $40 million in D3 Bio, a biotechnology company based in Shanghai, China.
The US-based investment fund is reportedly working to find partners in some of the data centers.
The deal will allow GDS International to obtain dedicated financing for the independent development of its international business.
GDS Holdings Limited misses on earnings expectations. Reported EPS is $-0.62 EPS, expectations were $-0.39.